Freedland SJ - Search Results

1

Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.

Ryan CJ, Ke X, Lafeuille MH, Romdhani H, Kinkead F, Lefebvre P, Petrilla A, Pulungan Z, Kim S, D'Andrea DM, Francis P, Freedland SJ. Ryan CJ, et al. Among authors: freedland sj. J Urol. 2021 Dec;206(6):1420-1429. doi: 10.1097/JU.0000000000002121. Epub 2021 Jul 23. J Urol. 2021. PMID: 34293915 Free PMC article.

2

Clinical characteristics in black and white men with prostate cancer in an equal access medical center.

Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Freedland SJ, et al. Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6. Urology. 2000. PMID: 10699616

3

Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Freedland SJ, et al. Urology. 2000 Jul;56(1):87-91. doi: 10.1016/s0090-4295(00)00587-2. Urology. 2000. PMID: 10869631

4

Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2000 Nov 1;56(5):807-11. doi: 10.1016/s0090-4295(00)00754-8. Urology. 2000. PMID: 11068307

5

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Urology. 2001 Mar;57(3):476-80. doi: 10.1016/s0090-4295(00)01016-5. Urology. 2001. PMID: 11248623

6

Collecting duct renal cell carcinoma: clinical study of a rare tumor.

Chao D, Zisman A, Pantuck AJ, Gitlitz BJ, Freedland SJ, Said JW, Figlin RA, Belldegrun AS. Chao D, et al. Among authors: freedland sj. J Urol. 2002 Jan;167(1):71-4. doi: 10.1016/s0022-5347(05)65385-2. J Urol. 2002. PMID: 11743278

7

Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1016/S0022-5347(01)69076-1. J Urol. 2002. PMID: 11792909

8

Changing concepts in the management of renal oncocytoma.

Chao DH, Zisman A, Pantuck AJ, Freedland SJ, Said JW, Belldegrun AS. Chao DH, et al. Among authors: freedland sj. Urology. 2002 May;59(5):635-42. doi: 10.1016/s0090-4295(01)01630-2. Urology. 2002. PMID: 11992832 Review. No abstract available.

9

Effect of ketorolac on renal function after donor nephrectomy.

Freedland SJ, Blanco-Yarosh M, Sun JC, Hale SJ, Elashoff DA, Rajfer J, Gritsch HA. Freedland SJ, et al. Urology. 2002 Jun;59(6):826-30. doi: 10.1016/s0090-4295(02)01514-5. Urology. 2002. PMID: 12031361

10

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Freedland SJ, et al. J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

778 results

Search Page

Filters